Literature DB >> 27598688

Isolation of Coralmycins A and B, Potent Anti-Gram Negative Compounds from the Myxobacteria Corallococcus coralloides M23.

Yu Jin Kim1, Hyun-Ju Kim1, Geon-Woo Kim1, Kyungyun Cho2, Shunya Takahashi3, Hiroyuki Koshino3, Won-Gon Kim1.   

Abstract

Two new potent anti-Gram negative compounds, coralmycins A (1) and B (2), were isolated from cultures of the myxobacteria Corallococcus coralloides M23, together with another derivative (3) that was identified as the very recently reported cystobactamid 919-2. Their structures including the relative stereochemistry were elucidated by interpretation of spectroscopic, optical rotation, and CD data. The relative stereochemistry of 3 was revised to "S*R*" by NMR analysis. The antibacterial activity of 1 was most potent against Gram-negative pathogens, including Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumanii, and Klebsiella pneumoniae, with MICs of 0.1-4 μg/mL; these MICs were 4-10 and 40-100 times stronger than the antibacterial activities of 3 and 2, respectively. Thus, these data indicated that the β-methoxyasparagine unit and the hydroxy group of the benzoic acid unit were critical for antibacterial activity.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27598688     DOI: 10.1021/acs.jnatprod.6b00294

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  8 in total

1.  Molecular and functional characterization of myxobacteria isolated from soil in India.

Authors:  Shiv Kumar; Arun Kumar Yadav; Priyanka Chambel; Ramandeep Kaur
Journal:  3 Biotech       Date:  2017-05-31       Impact factor: 2.406

2.  Corallococcus soli sp. Nov., a Soil Myxobacterium Isolated from Subtropical Climate, Chalus County, Iran, and Its Potential to Produce Secondary Metabolites.

Authors:  Zahra Khosravi Babadi; Ronald Garcia; Gholam Hossein Ebrahimipour; Chandra Risdian; Peter Kämpfer; Michael Jarek; Rolf Müller; Joachim Wink
Journal:  Microorganisms       Date:  2022-06-21

Review 3.  Natural and Synthetic Oligoarylamides: Privileged Structures for Medical Applications.

Authors:  Tim Seedorf; Andreas Kirschning; Danny Solga
Journal:  Chemistry       Date:  2021-03-04       Impact factor: 5.236

4.  Myxobacteria Are Able to Prey Broadly upon Clinically-Relevant Pathogens, Exhibiting a Prey Range Which Cannot Be Explained by Phylogeny.

Authors:  Paul G Livingstone; Russell M Morphew; David E Whitworth
Journal:  Front Microbiol       Date:  2017-08-22       Impact factor: 5.640

5.  Cystobactamid 507: Concise Synthesis, Mode of Action, and Optimization toward More Potent Antibiotics.

Authors:  Walid A M Elgaher; Mostafa M Hamed; Sascha Baumann; Jennifer Herrmann; Lorenz Siebenbürger; Jana Krull; Katarina Cirnski; Andreas Kirschning; Mark Brönstrup; Rolf Müller; Rolf W Hartmann
Journal:  Chemistry       Date:  2020-04-28       Impact factor: 5.236

6.  Antibacterial Activity against Clinical Isolates and In Vivo Efficacy of Coralmycins.

Authors:  Ha-Young Choi; Bo-Min Kim; Young-Rok Kim; Taehui Yang; Sunjoo Ahn; Dongeun Yong; Jin-Hwan Kwak; Won-Gon Kim
Journal:  Antibiotics (Basel)       Date:  2022-07-06

7.  Synthetic studies of cystobactamids as antibiotics and bacterial imaging carriers lead to compounds with high in vivo efficacy.

Authors:  Giambattista Testolin; Katarina Cirnski; Katharina Rox; Hans Prochnow; Verena Fetz; Charlotte Grandclaudon; Tim Mollner; Alain Baiyoumy; Antje Ritter; Christian Leitner; Jana Krull; Joop van den Heuvel; Aurelie Vassort; Sylvie Sordello; Mostafa M Hamed; Walid A M Elgaher; Jennifer Herrmann; Rolf W Hartmann; Rolf Müller; Mark Brönstrup
Journal:  Chem Sci       Date:  2019-12-10       Impact factor: 9.825

8.  Molecular insights into antibiotic resistance - how a binding protein traps albicidin.

Authors:  Lida Rostock; Ronja Driller; Stefan Grätz; Dennis Kerwat; Leonard von Eckardstein; Daniel Petras; Maria Kunert; Claudia Alings; Franz-Josef Schmitt; Thomas Friedrich; Markus C Wahl; Bernhard Loll; Andi Mainz; Roderich D Süssmuth
Journal:  Nat Commun       Date:  2018-08-06       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.